Business Card for Leslie Jacobson:


Oncology Sales Specialists
Los Angeles, CA area


100 Tice Blvd
Woodcliff Lake, NJ 07677

Tel: (201) 692-1100

Last updated on 2017-03-08


About Leslie Jacobson:

Leslie Jacobson works as an Oncology Sales Specialists for Eisai Inc. at Los Angeles, CA. The company's webpage is http://www.eisai.com. For email, phone number and executive profiles for Oncology Sales Specialists and other executives of Eisai Inc. at Los Angeles, CA, check Eisai Inc. at Joesdata.com. Not the Leslie Jacobson you are looking for? Do a quick search in our website and find other people named Leslie Jacobson.
Leslie Jacobson's Work History:
No information available..

Leslie Jacobson's Education:
No information available..

Leslie Jacobson's Co-workers:
As of December 5, 2019, Leslie Jacobson has 101 co-workers under the company name Eisai Inc. at Joesdata.com.

About Eisai Inc.:


Warning: mysqli_fetch_assoc() expects parameter 1 to be mysqli_result, boolean given in /home2/joesdata/public_html/login/executivedetails.php on line 392
Eisai Inc. is located at 100 Tice Blvd , Woodcliff Lake, NJ 07677. It has around 5K - 10K employees. Its revenue is around $500M - 1B.

Company News:
2018-09-04 02:35:04
Stephen Davies Appointed Vice President, Eisai Strategic Information Systems at Eisai Inc.
2018-08-23 17:42:27
Eisai and Merck Announce European Commission Grants Marketing Authorization for LENVIMA (lenvatinib) as First-Line Treatment in Adults with Advanced or Unresectable Hepatocellular Carcinoma
2018-08-23 17:30:36
Eisai and Merck Announce European Commission Grants Marketing Authorization for LENVIMA (lenvatinib) as First-Line Treatment in Adults with Advanced or Unresectable Hepatocellular Carcinoma
2018-03-23 17:31:49
Anticancer Agent LENVIMA (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC
2018-03-23 17:06:53
Anticancer Agent LENVIMA (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC
2017-10-03 20:13:30
Eisai Inc. and Grupo Biotoscana Sign Exclusive Licensing Agreement for the Commercialization of Eisai's Oncology and Neurology Products throughout Latin America
2017-09-25 20:01:21
Michael Amoroso appointed Senior Vice President, Americas Commercial, Oncology Business Group at Eisai Inc.
2017-08-31 21:37:16
Eisai to Present New Clinical Data in Variety of Advanced Cancers at the ESMO 2017 Congress
2017-07-09 20:48:55
Nuovi dati evidenziano i risultati di lenvatinib vs sorafenib in uno studio di prima linea sul carcinoma epatico
2017-05-31 20:12:50
Eisai and Johns Hopkins Extend Drug Discovery Collaboration with New Licensing Agreement

People in the same industry: